|Continuum Health Partners: Beth Israel • Roosevelt Hospital and St. Luke's Hospital • Long Island College Hospital • New York Eye and Ear Infirmary|
|Home | Find A Doctor | Contact Us|
LUX: An open label, randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prior trastuzumab treatment
The purpose of this research study is to test the safety and effectiveness of the investigational drug, BIBW 2992, combined with vinorelbine compared to trastuzumab combined with vinorelbine in subjects with metastatic breast cancer who failed one prior trastuzumab treatment.
There are two study drug treatment groups in this research study:
Vinorelbine has previously been tested in combination with trastuzumab and has shown lower toxicity than with other trastuzumab combination therapies.
Please call for more information
Copyright © 2008